Company Overview

PRIME exits® and American Healthcare Capital are proud to be the exclusive representative of a leading, physician-founded, multispecialty chronic-care platform operating as an MSO (Medical Service Organization Model) in the Southwestern United States. The group is seeking a strategic or capital partner to accelerate its next phase of expansion through targeted acquisitions and new de-novo centers. With nearly two decades of operating history, the company has built one of the most comprehensive and payer-integrated wound care and vascular management platforms in the region, offering an exceptional opportunity for investors seeking exposure to the fastest-growing sectors in healthcare—chronic disease management, diabetic care, and limb preservation.

The company currently operates multiple state-of-the-art outpatient facilities and a fully equipped vascular and vein lab, delivering an integrated continuum of care that includes wound management, infectious disease, podiatry, endocrinology, and vascular surgery. Its model is designed around patient outcomes and cost reduction, with services extending into home-based wound care and DME supply delivery in the near future, to ensure continuity across the patient journey. The result is a scalable, diversified platform with recurring revenue streams across outpatient, procedural, and home-care verticals.

Preferred Provider Network and Market Position

What truly sets this organization apart is its unmatched payer alignment. It holds preferred provider status with nearly all major commercial insurers and Medicare Advantage plans in its region, granting access to over 800,000 covered lives. This includes multiple large health systems and managed care entities where the company has become the default outpatient wound and vascular referral provider—a rare status in this fragmented sector.

By delivering hospital-quality care in freestanding facilities without facility fees, the company significantly lowers costs for payers and patients alike. This cost-efficiency, combined with demonstrable reductions in hospital readmissions and amputations, has fueled consistent growth and made the company a sought-after partner among insurers seeking innovative, value-based care models.

Financial Performance and Growth Trajectory

Over the past three years, the company’s revenue has grown from approximately $7.2 million in 2022 to $10.8 million in 2024, reflecting a compound annual growth rate (CAGR) exceeding 20%. The management projects a $10 million revenue in 2025 but a temporary and a significant drop in EBITDA this year due to various investments and expansion activities.

Forecasted 2025–2026 Projection

Based on prior three-year revenue CAGR of ~22% and normalization of 2025 YTD variances (seasonality and recent expansion costs), full-year 2025 revenue is projected at $10 million, with an EBITDA recovery in 2026 to $2.4–$2.6 million.

2026 projections incorporate expected stabilization of the newly opened facility and added vascular volume, and are estimated to be:

• Revenue: ~$12.0–$12.5 million

• EBITDA: ~$2.4–$2.6 million

• EBITDA Margin: ~20–21%

Expansion Opportunities

The company is poised for both horizontal and vertical expansion. Immediate targets include:

• Regional roll-ups of podiatry and home-health groups to consolidate chronic-care services under one unified payer structure.

• Launch of new de-novo centers in underserved diabetic and vascular markets in other locations as well as neighboring states.

• Addition of IV infusion services and a 340B pharmacy program, enhancing recurring revenue potential.

• Pursuit of an Ambulatory Surgical Center (ASC) license to elevate procedural capacity and margin capture.

This strategy aims to replicate the company’s successful regional model and scale it to a multi-state chronic-care platform spanning 15–20 locations across 4–5 states within five to seven years.

Leadership and Vision

Led by a nationally recognized physician with over two decades of experience in wound care and vascular medicine, the company combines deep clinical expertise with strong operational leadership. The founder remains committed to staying with the business post-transaction, either as a partner or minority equity holder, to guide its continued growth and integration efforts.

Investment Rationale

This opportunity represents an acquisition of a rare and a ready-to-scale platform in the outpatient chronic-care space with the following distinguishing features:

• Fully integrated, multispecialty model spanning wound care, vascular, podiatry, endocrinology, and infectious disease.

• Preferred payer relationships across major commercial and government plans.

• Recurring, diversified revenue with strong EBITDA performance.

• Proven scalability through both acquisitions and de-novo site replication.

• An experienced founder open to flexible deal structures and long-term collaboration.

In an era when chronic disease management and cost efficiency are central to healthcare reform, this company stands at the intersection of clinical excellence, financial performance, and scalability. It offers the right strategic or capital partner the opportunity to build a regional—and ultimately national—Center of Excellence network for diabetic and vascular care, capable of commanding premium valuations at exit.

Asking Price and Valuation

The business is being offered at an asking price of $10,000,000, plus an earn-out structure tied to 2026 performance. This pricing reflects a conservative 6.0–6.3x multiple on forward EBITDA, making it an attractive entry point for buyers seeking growth through operational leverage, payer partnerships, and bolt-on acquisitions. The price excludes Cash, Accounts Receivables, Excess Inventory, Working Capital and any Real Estate Holdings.